hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06374979, orgStudyIdInfo id: 2024-0047, briefTitle: Efficacy and Safety of Ixekizumab in Patients With Refractory Guttate Psoriasis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Second Affiliated Hospital, School of Medicine, Zhejiang University, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to analyse efficacy and safety of ixekizumab in participants with refractory guttate psoriasis. The main question it aims to answer is:What percentage of participants achieved more than 90% reduction from baseline in Psoriasis Area Index （PASI 90） after 12 weeks of ixekizumab treatment? Participants will receive a 12-week treatment of ixekizumab, with follow-up visits every 2 weeks during the treatment period. Keep a diary of their symptoms and Psoriasis Area Index., conditionsModule conditions: Guttate Psoriasis, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Ixekizumab, outcomesModule primaryOutcomes measure: PASI 90 response, secondaryOutcomes measure: PGA 0/1 response, secondaryOutcomes measure: PASI 100 response, secondaryOutcomes measure: Relapse, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06374953, orgStudyIdInfo id: 2024-0182, briefTitle: A Novel Viscoelastic Test Based on Ultrasonic Guided Wave for Identifying Hyperfibrinolysis Rapidly, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-26, primaryCompletionDateStruct date: 2024-09-30, completionDateStruct date: 2024-09-30, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Second Affiliated Hospital, School of Medicine, Zhejiang University, class: OTHER, descriptionModule briefSummary: This study compares the results of the existing fibrinolysis monitoring technology to the Ultrasound-based viscoelastic hemostasis analysis, a new method, using small amount of extra blood obtained during routine blood draws in surgery patients., conditionsModule conditions: Hyperfibrinolysis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 140, type: ESTIMATED, armsInterventionsModule interventions name: Ultrasound-based viscoelastic hemostasis analysis, outcomesModule primaryOutcomes measure: Comparison of the novel viscoelastic hemostasis analysis results to TEG-LY30, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Second Affiliated Hospital of Zhejiang University anesthesiology department, status: RECRUITING, city: Hangzhou, state: Zhejiang, zip: 310009, country: China, contacts name: Fengjiang ZHANG, role: CONTACT, phone: +8613858007629, email: zrzfj@zju.eud.cn, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06374940, orgStudyIdInfo id: Lütfi Kırdar City Hospital, briefTitle: Surgical Outcomes of Conventional Hysterectomy or Manipulator-assisted Abdominal Hysterectomy, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-04-17, primaryCompletionDateStruct date: 2024-05-17, completionDateStruct date: 2024-05-18, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Dr. Lutfi Kirdar Kartal Training and Research Hospital, class: OTHER_GOV, descriptionModule briefSummary: Objective: The comparison of surgical outcomes conventional hysterectomy and manipulator-assisted hysterectomyStudy design: Prospective randomized controlled trial. Allocation to either group occurred via computer-generated random numbers. Sequentially numbered, opaque envelopes were prepared according to randomization. The patients were unaware of whether they would undergo a conventional hysterectomy or manipulator-assisted abdominal hysterectomy for their surgical procedure. The research coordinator unveiled group assignments upon individual patient recruitment by opening the corresponding envelope.Study population: Inclusion criteria were patients aged 40-70 years who underwent hysterectomy for benign gynecological indications.Primary outcomes: (1) Operation Time.Secondary outcomes: (1) Postoperative early pain (Visual Analog Score (VAS) at 6th and 24th hours of the surgery) (2) intraoperative complications, (3) postoperative complications, conditionsModule conditions: Gynecologic Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 140, type: ESTIMATED, armsInterventionsModule interventions name: Manipulator-assisted Abdominal Hysterectomy, outcomesModule primaryOutcomes measure: Duration of the surgical procedure, secondaryOutcomes measure: Postoperative pain at 6th hours, secondaryOutcomes measure: Postoperative pain at 24th hours, secondaryOutcomes measure: intraoperative complications, secondaryOutcomes measure: Postoperative complications, eligibilityModule sex: FEMALE, minimumAge: 40 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dr.Lütfi Kırdar City Hospital, city: Istanbul, zip: 34000, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06374914, orgStudyIdInfo id: TUO-UR-23-05, briefTitle: Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-09, primaryCompletionDateStruct date: 2026-04-09, completionDateStruct date: 2026-04-09, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Dokuz Eylul University, class: OTHER, descriptionModule briefSummary: Studies in the literature are limited both throughout Turkey and in general. For this reason, as a result of the study that we will create, it will provide us with information for bladder protective treatments in patients who do not respond to BCG therapy in bladder cancer patients., conditionsModule conditions: Bladder Cancer, conditions: BCG, conditions: Gemcitabine, conditions: Docetaxel, conditions: Intravesical Instillation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Intravesical Solution, outcomesModule primaryOutcomes measure: Recurrence rate, primaryOutcomes measure: Progression rate, primaryOutcomes measure: Adverse effects of intravesical chemotherapy, primaryOutcomes measure: Intravesical chemotherapy versus radical cystectomy, secondaryOutcomes measure: treatment change, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dokuz Eylul University Faculty of Medicine Department of Urology, city: Izmir, state: Other (Non U.s.), zip: 35330, country: Turkey, contacts name: Muhammed Selcuk Ozer, Medical Doctor, role: CONTACT, phone: +905543078941, email: mseljukozer@gmail.com, contacts name: Ozan Bozkurt, Professor, role: CONTACT, email: drozanbozkurt@gmail.com, contacts name: Ozan Bozkurt, Professor, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 38.41273, lon: 27.13838, hasResults: False
protocolSection identificationModule nctId: NCT06374901, orgStudyIdInfo id: IRB-2024-311, briefTitle: Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-25, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2028-03-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Xiangdong Cheng, class: OTHER, collaborators name: Liaoning Tumor Hospital & Institute, collaborators name: Shanxi Province Cancer Hospital, collaborators name: Sichuan Cancer Hospital and Research Institute, collaborators name: The Second Affiliated Hospital of Harbin Medical University, descriptionModule briefSummary: To evaluate the efficacy of Tislelizumab in combination with chemotherapy versus chemotherapy in neoadjuvant treatment of patients with MHC-II positive (IHC≥2+) and locally advanced gastric/gastroesophageal junction adenocarcinoma by evaluating the main pathologic response rate (MPR)., conditionsModule conditions: Gastric Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 134, type: ESTIMATED, armsInterventionsModule interventions name: Tislelizumab, interventions name: SOX/XELOX, outcomesModule primaryOutcomes measure: MRP (Main pathological response), secondaryOutcomes measure: pCR (pathologic complete response), secondaryOutcomes measure: DFS (Disease free survival), secondaryOutcomes measure: OS (Overall survival), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), city: Hangzhou, state: Zhejiang, country: China, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06374888, orgStudyIdInfo id: CVL009-2002, briefTitle: Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2026-09-30, completionDateStruct date: 2027-07-30, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Convalife (Shanghai) Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: To evaluate the efficacy of nilatinib maleate tablets combined with capecitabine in the treatment of HER2-positive advanced esophageal/esophagogastric junction/gastric adenocarcinoma with brain metastasis., conditionsModule conditions: Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Her2-positive advanced esophageal/esophagogastric junction/gastric adenocarcinoma with brain metastases, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 28, type: ESTIMATED, armsInterventionsModule interventions name: Neratinib maleate in combination with capecitabine, outcomesModule primaryOutcomes measure: Objective response rates of the central nervous system as assessed by the Independent Imaging Evaluation Committee based on RECIST1.1, secondaryOutcomes measure: Central nervous response rate, secondaryOutcomes measure: Objective response rates outside the central nervous system, secondaryOutcomes measure: Disease control rate, secondaryOutcomes measure: Duration of reaction, secondaryOutcomes measure: Clinical benefit rate, secondaryOutcomes measure: overall survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06374862, orgStudyIdInfo id: PI2024_843_0008, briefTitle: Effects of Specific Thoracic Spine Mobilizations on Muscle Activity in a Healthy Volunteer Population, acronym: RACHI-MOB, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-28, primaryCompletionDateStruct date: 2025-10, completionDateStruct date: 2025-10, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Universitaire, Amiens, class: OTHER, descriptionModule briefSummary: In this study, the investigators will examine the effect of manual therapy on the thoracic spine and its impact on the muscular strength gain of the thoracic extensors. Treatment with manual therapy, as described by Maitland, consists of a specific mobilization of the thoracic spine in the postero-anterior direction on the transverse and spiny processes of the thoracic vertebrae. To ensure the relevance of the measures, and to better control the occurrence of biases inherent to the practice of manual therapy, the investigators constituted three distinct groups: an intervention group, a control group and a group without intervention. In short, this methodology will allow us to explore in detail the effects of specific spinal mobilization on motor control, while taking into account placebo response elements and natural variations in the results, conditionsModule conditions: Musculoskeletal Manipulations, conditions: Range of Motion, conditions: Muscle Strength, conditions: Peripheral Joints in Upper Quarters, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 156, type: ESTIMATED, armsInterventionsModule interventions name: mobilization, interventions name: no effect, outcomesModule primaryOutcomes measure: electrical activity assessment of the spine extensor muscles using EMG, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHU Amiens Picardie, status: RECRUITING, city: Amiens, state: Picardie, zip: 80054, country: France, contacts name: Vicente BELTRAN AIBAR, role: CONTACT, phone: 03.22.45.59.92, email: BeltranAibar.Vicente@chu-amiens.fr, contacts name: François-Régis Sarhan, role: SUB_INVESTIGATOR, geoPoint lat: 49.9, lon: 2.3, hasResults: False
protocolSection identificationModule nctId: NCT06374849, orgStudyIdInfo id: PI2023_843_0173, briefTitle: Intraoperative Sufentanil and Chronic Postsurgical Pain in Non-major Scheduled Abdominal Surgery, acronym: ISPAIN, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-17, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2026-07, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Universitaire, Amiens, class: OTHER, descriptionModule briefSummary: Several risk factors for chronic postoperative pain have been identified. A series of studies have shown that administrating intraoperatively a high dose of Remifentanil is associated with an increased incidence of CPSP. These findings highlight a risk factor for CPSP that the anaesthetist can influence on, but they however remain limited to remifentanil. To this day, no study have attempted to evaluate the existence of such an association between the incidence of CPSP and the intraoperative administration of sufentanil doses. Improved knowledge of the long-term nociceptive impact of intraoperative sufentanil administration would enable better therapeutic adaptation according to each patient's risk.In the field of CPSP, non-major abdominal surgeries remain poorly studied. This is due to their lower risk of CPSP than other surgeries such as orthopaedic, mammary or thoracic surgery. Nevertheless, they constitute a large number of daily surgical procedures. The estimated incidence of CPSP in non-major abdominal surgery appears in several studies to be between 15 and 20% The aim of this study is to evaluate the correlation between the intraoperative administration of sufentanil doses and the incidence of CPSP at 3 months in patients undergoing non-major scheduled abdominal surgery., conditionsModule conditions: Chronic Postsurgical Pain, conditions: Chronic Pain, conditions: Abdominal Surgery, conditions: Sufentanil, conditions: Risk Factors, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 855, type: ESTIMATED, armsInterventionsModule interventions name: phone interview, outcomesModule primaryOutcomes measure: Incidence of CPSP, secondaryOutcomes measure: Post-operative pain intensity, secondaryOutcomes measure: Post-operative pain intensity, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHU Amiens-Picardie, status: RECRUITING, city: Amiens, zip: 80054, country: France, contacts name: Paul TARPIN, MD, role: CONTACT, phone: 0322087980, email: Tarpin.Paul@chu-amiens.fr, contacts name: Ottilie Fumery, MD, role: SUB_INVESTIGATOR, contacts name: Stephane BAR, Pr, role: SUB_INVESTIGATOR, contacts name: Benjamin Mestan, MD, role: SUB_INVESTIGATOR, geoPoint lat: 49.9, lon: 2.3, hasResults: False
protocolSection identificationModule nctId: NCT06374823, orgStudyIdInfo id: IIT2023-020-002, briefTitle: Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke, acronym: MERIT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-12, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Capital Medical University, class: OTHER, descriptionModule briefSummary: Normal saline (0.9% sodium chloride), a classical crystalloid solution, is widely used to maintain fluid balance, volume resuscitation and dilute drugs during clinical practice. However, the chloride concentration of normal saline (154mmol/L) is much higher than human plasma, and a large amount of infusion may lead to iatrogenic hyperchloremia in ICU patients. In contrast, the concentrations of Multiple electrolytes II is more similar to those of plasma and is considered to be a better fluid choice than normal saline., conditionsModule conditions: Critical Care, conditions: Hyperchloremia, conditions: Hemorrhagic Stroke, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 342, type: ESTIMATED, armsInterventionsModule interventions name: Multiple Electrolyte, interventions name: Normal Saline, outcomesModule primaryOutcomes measure: Hyperchloremia, secondaryOutcomes measure: Hyperchloremia acidosis, secondaryOutcomes measure: Plasma osmolality, secondaryOutcomes measure: AKI, secondaryOutcomes measure: RRT, secondaryOutcomes measure: hospital length of stay, secondaryOutcomes measure: ICU length of stay, secondaryOutcomes measure: hospitalization expense, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Shijitan Hospital, city: Beijing, state: Beijing, zip: 100038, country: China, contacts name: Jian-Xin Zhou, MD, role: CONTACT, phone: +8613801183875, email: zhoujx.cn@icloud.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06374810, orgStudyIdInfo id: CCB1, briefTitle: Does Conscious Connected Breathwork Reduce Symptoms of Anxiety?, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-09-21, primaryCompletionDateStruct date: 2023-12-20, completionDateStruct date: 2023-12-20, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Richard Blake, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to test whether conscious connected breathwork reduces symptoms of anxiety in people with mild to severe anxiety symptoms, as measured by the Zung Self Rating Anxiety Scale.The main questions aims to answer:1. Does conscious connected breathwork reduce symptoms of anxiety?2. Does an increased frequency of self-practice lead to even greater reductions of anxiety symptoms.there is a comparison group: Researchers will compare whether people doing the breathwork to see if \[insert effects\].Participants will participate in 1, 90 minute breath workshop per week for 6 weeks. These sessions will be held on Zoom by 2 facilitators. Participants will also be given a 10 minute recording of a guided conscious connected breathwork session that they will be encouraged to complete daily., conditionsModule conditions: Anxiety, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Participants were randomly assigned to either the breathwork group or they were told that they had been placed on a waitlist and that they would participate in the 2nd cohort, which would take place after the 1st 6-week program had been completed.Participants in the breathwork groups were also given a 10 minute guided conscious connected breathwork recording. They were advised to do this daily to support the integration of their process. This was not mandatory. At the end of the study participants were asked how often they used the guided self-practice. The frequency of use of the self-practice was used a covariate., primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: Participants in group 2 were told that the trial was full but actually they were just placed in the placebo control group., whoMasked: PARTICIPANT, enrollmentInfo count: 108, type: ACTUAL, armsInterventionsModule interventions name: Conscious Connected Breathwork, interventions name: Placebo waitlist, outcomesModule primaryOutcomes measure: Changes in anxiety symptoms, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CIIS, city: San Francisco, state: California, zip: 94103, country: United States, geoPoint lat: 37.77493, lon: -122.41942, hasResults: False